Premium
Desirable cell death during anticancer chemotherapy
Author(s) -
Locher Clara,
Conforti Rosa,
Aymeric Laetitia,
Ma Yuting,
Yamazaki Takahiro,
Rusakiewicz Sylvie,
Tesnière Antoine,
Ghiringhelli François,
Apetoh Lionel,
Morel Yannis,
Girard JeanPhilippe,
Kroemer Guido,
Zitvogel Laurence
Publication year - 2010
Publication title -
annals of the new york academy of sciences
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.712
H-Index - 248
eISSN - 1749-6632
pISSN - 0077-8923
DOI - 10.1111/j.1749-6632.2010.05763.x
Subject(s) - immunogenic cell death , immunogenicity , priming (agriculture) , immune system , chemotherapy , cytotoxic t cell , programmed cell death , apoptosis , cancer research , t cell , immunology , cell , immunotherapy , biology , medicine , in vitro , biochemistry , botany , germination , genetics
The concept of immunogenic chemotherapy that has recently emerged relies upon the capacity of a cytotoxic compound to trigger a cell‐death modality. This modality elicits cross‐priming by dendritic cells of tumor antigen‐specific T cells that will contribute to the tumoricidal activity of the compound and protect the host against relapse. In contrast, most anticancer drugs elicit nonimmunogenic apoptosis that is not accompanied with an immunizing property. This review will discuss some molecular and metabolic changes required at the level of the tumor that must engage key pathways at the level of the host for the induction of Tc1 polarized–protective T cell responses during chemotherapy. We will summarize the immune adjuvants that can boost the immunogenicity of cell death to augment the efficacy of chemotherapy.